ALX Oncology (ALXO) Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
January 5, 2023 7:00 AM ESTSOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023.
2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology. Marked by steady progress in the clinical development of our lead program, evorpacept, for the treatment of multiple solid tumor indications and hematological malignancies, we expanded clinical development of evorpacept in new indications and combinations. These included a Phase 1 trial in... More
